 |
||||
|
||||
|
||||
|
||||
The Journal of Neuroscience, March 23, 2005, 25(12):3126-3131; doi:10.1523/JNEUROSCI.3815-04.2005
Previous Article | Next Article
BRIEF COMMUNICATION
Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain
Joseph R. Ghilardi,1,2 Heidi Röhrich,1 Theodore H. Lindsay,1 Molly A. Sevcik,1 Matthew J. Schwei,1 Kazufumi Kubota,1 Kyle G. Halvorson,1 Jeannie Poblete,4 Sandra R. Chaplan,5 Adrienne E. Dubin,5 Nicholas I. Carruthers,5 Devin Swanson,5 Michael Kuskowski,3 Christopher M. Flores,6 David Julius,4 andPatrick W. Mantyh1,2 1Neurosystems Center and Departments of Preventive Sciences, Psychiatry, Neuroscience, and Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, 2Research Service and 3Geriatric Research, Education, and Clinical Center, Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, 4Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California 94143-2140, 5Johnson and Johnson Pharmaceutical Research and Development, San Diego, California 92121, and 6Johnson and Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania 19446
Cancer colonization of bone leads to the activation of osteoclasts, thereby producing local tissue acidosis and bone resorption. This process may contribute to the generation of both ongoing and movement-evoked pain, resulting from the activation of sensory neurons that detect noxious stimuli (nociceptors). The capsaicin receptor TRPV1 (transient receptor potential vanilloid subtype 1) is a cation channel expressed by nociceptors that detects multiple pain-producing stimuli, including noxious heat and extracellular protons, raising the possibility that it is an important mediator of bone cancer pain via its capacity to detect osteoclast- and tumor-mediated tissue acidosis. Here, we show that TRPV1 is present on sensory neuron fibers that innervate the mouse femur and that, in an in vivo model of bone cancer pain, acute or chronic administration of a TRPV1 antagonist or disruption of the TRPV1 gene results in a significant attenuation of both ongoing and movement-evoked nocifensive behaviors. Administration of the antagonist had similar efficacy in reducing early, moderate, and severe pain-related responses, suggesting that TRPV1 may be a novel target for pharmacological treatment of chronic pain states associated with bone cancer metastasis.
Key words: tumor; skeletal malignancies; vanilloid receptor; metastasis; nociception; therapy
Received Sep 14, 2004; revised February 1, 2005; accepted February 1, 2005.
This article has been cited by other articles:
S. G. Lehto, R. Tamir, H. Deng, L. Klionsky, R. Kuang, A. Le, D. Lee, J.-C. Louis, E. Magal, B. H. Manning, et al.
Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 218 - 229.
[Abstract] [Full Text] [PDF]
Y. V. Medvedeva, M.-S. Kim, and Y. M. Usachev
Mechanisms of Prolonged Presynaptic Ca2+ Signaling and Glutamate Release Induced by TRPV1 Activation in Rat Sensory Neurons
J. Neurosci., May 14, 2008; 28(20): 5295 - 5311.
[Abstract] [Full Text] [PDF]
K. Schnizler, L. P. Shutov, M. J. Van Kanegan, M. A. Merrill, B. Nichols, G. S. McKnight, S. Strack, J. W. Hell, and Y. M. Usachev
Protein Kinase A Anchoring via AKAP150 Is Essential for TRPV1 Modulation by Forskolin and Prostaglandin E2 in Mouse Sensory Neurons
J. Neurosci., May 7, 2008; 28(19): 4904 - 4917.
[Abstract] [Full Text] [PDF]
C. E. Constantin, N. Mair, C. A. Sailer, M. Andratsch, Z.-Z. Xu, M. J. F. Blumer, N. Scherbakov, J. B. Davis, H. Bluethmann, R.-R. Ji, et al.
Endogenous Tumor Necrosis Factor {alpha} (TNF{alpha}) Requires TNF Receptor Type 2 to Generate Heat Hyperalgesia in a Mouse Cancer Model
J. Neurosci., May 7, 2008; 28(19): 5072 - 5081.
[Abstract] [Full Text] [PDF]
N. R. Gavva, A. W. Bannon, D. N. Hovland Jr., S. G. Lehto, L. Klionsky, S. Surapaneni, D. C. Immke, C. Henley, L. Arik, A. Bak, et al.
Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 128 - 137.
[Abstract] [Full Text] [PDF]
I. A. Khasabova, C. L. Stucky, C. Harding-Rose, L. Eikmeier, A. J. Beitz, L. G. Coicou, A. E. Hanson, D. A. Simone, and V. S. Seybold
Chemical Interactions between Fibrosarcoma Cancer Cells and Sensory Neurons Contribute to Cancer Pain
J. Neurosci., September 19, 2007; 27(38): 10289 - 10298.
[Abstract] [Full Text] [PDF]
M. Trevisani, J. Siemens, S. Materazzi, D. M. Bautista, R. Nassini, B. Campi, N. Imamachi, E. Andre, R. Patacchini, G. S. Cottrell, et al.
4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1
PNAS, August 14, 2007; 104(33): 13519 - 13524.
[Abstract] [Full Text] [PDF]
M. J. Gunthorpe, S. L. Hannan, D. Smart, J. C. Jerman, S. Arpino, G. D. Smith, S. Brough, J. Wright, J. Egerton, S. C. Lappin, et al.
Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor
J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1183 - 1192.
[Abstract] [Full Text] [PDF]
N. R. Gavva, A. W. Bannon, S. Surapaneni, D. N. Hovland Jr, S. G. Lehto, A. Gore, T. Juan, H. Deng, B. Han, L. Klionsky, et al.
The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation
J. Neurosci., March 28, 2007; 27(13): 3366 - 3374.
[Abstract] [Full Text] [PDF]
T. K. Pareek, J. Keller, S. Kesavapany, N. Agarwal, R. Kuner, H. C. Pant, M. J. Iadarola, R. O. Brady, and A. B. Kulkarni
Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1
PNAS, January 9, 2007; 104(2): 660 - 665.
[Abstract] [Full Text] [PDF]
B. Nilius, G. Owsianik, T. Voets, and J. A. Peters
Transient Receptor Potential Cation Channels in Disease
Physiol Rev, January 1, 2007; 87(1): 165 - 217.
[Abstract] [Full Text] [PDF]
M. J. Goblirsch, P. P. Zwolak, and D. R. Clohisy
Biology of bone cancer pain.
Clin. Cancer Res., October 15, 2006; 12(20): 6231s - 6235s.
[Abstract] [Full Text] [PDF]
L. Klionsky, R. Tamir, B. Holzinger, X. Bi, J. Talvenheimo, H. Kim, F. Martin, J.-C. Louis, J. J. S. Treanor, and N. R. Gavva
A Polyclonal Antibody to the Prepore Loop of Transient Receptor Potential Vanilloid Type 1 Blocks Channel Activation
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 192 - 198.
[Abstract] [Full Text] [PDF]
J. Yagi, H. N. Wenk, L. A. Naves, and E. W. McCleskey
Sustained Currents Through ASIC3 Ion Channels at the Modest pH Changes That Occur During Myocardial Ischemia
Circ. Res., September 1, 2006; 99(5): 501 - 509.
[Abstract] [Full Text] [PDF]
N. R. Gavva, R. Tamir, L. Klionsky, M. H. Norman, J.-C. Louis, K. D. Wild, and J. J. S. Treanor
Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1
Mol. Pharmacol., December 1, 2005; 68(6): 1524 - 1533.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|